Senti Biosciences authorizes $2 million senior secured convertible note issuance to NSG BioInnovation Fund
SNTI•Additional note issuance authorized
Senti Biosciences amended its securities purchase agreement to allow additional tranches of Midco Senior Secured Convertible Notes.
The company authorized a third-tranche issuance of $2 million aggregate principal of the notes to NSG BioInnovation Fund.
Closing expected within three business days
Closing is expected within three business days of Sept. 1, 2026, subject to customary closing conditions.
NSG’s purchase is set to satisfy Celadon Partners SPV 35’s remaining obligation to purchase notes under the merger agreement.
